| Price | 1,858.50p on 07-05-2026 at 18:25:09 |
|---|---|
| Change | -16.50p -0.88% |
| Buy | 1,864.50p |
| Sell | 1,863.50p |
| Last Trade: | Unknown 3,616.00 at 1,873.246p |
| Day's Volume: | 14,942,427 |
| Last Close: | 1,858.50p |
| Open: | 1,878.00p |
| ISIN: | GB00BN7SWP63 |
| Day's Range | 1,855.50p - 1,886.50p |
| 52wk Range: | 1,315.00p - 2,282.00p |
| Market Capitalisation: | £74.62b |
| VWAP: | 1,871.472p |
| Shares in Issue: | 4.02b |
Glaxosmithkline (GSK) Latest Trades |
||||
| Buy/Sell | Volume | Trade Prc | Trade Type | Trade Time |
|---|---|---|---|---|
| Unknown* | 3,616 | 1,873.246p | OTC Trade |
17:35:11 - 07-May-26 |
| Buy* | 946 | 1,858.50p | SI Trade Negotiated Trade |
16:48:34 - 07-May-26 |
| Buy* | 7,044 | 1,858.50p | SI Trade Negotiated Trade |
16:48:34 - 07-May-26 |
| Buy* | 18,893 | 1,868.52p | SI Trade Negotiated Trade |
16:47:06 - 07-May-26 |
| Buy* | 4,165 | 1,858.50p | Automatic Execution |
16:39:19 - 07-May-26 |
| Buy* | 400 | 1,858.50p | Automatic Execution |
16:37:31 - 07-May-26 |
| Buy* | 800 | 1,858.50p | Automatic Execution |
16:37:31 - 07-May-26 |
| Buy* | 4,000 | 1,858.50p | Automatic Execution |
16:37:30 - 07-May-26 |
| Buy* | 200 | 1,858.50p | Automatic Execution |
16:37:30 - 07-May-26 |
| Buy* | 600 | 1,858.50p | Automatic Execution |
16:37:30 - 07-May-26 |
Glaxosmithkline (GSK) Regulatory News |
||
| Date | Source | Headline |
|---|---|---|
| 6th May 2026 6:22 pm | RNS | Result of AGM |
| 5th May 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 1st May 2026 3:00 pm | RNS | Holding(s) in Company |
| 1st May 2026 3:00 pm | RNS | Total Voting Rights |
| 29th Apr 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 29th Apr 2026 7:00 am | RNS | 1st Quarter Results |
| 28th Apr 2026 3:30 pm | RNS | Director/PDMR Shareholding |
| 28th Apr 2026 7:00 am | RNS | Bepirovirsen priority review US filing acceptance |
| 27th Apr 2026 12:00 pm | RNS | Efimosfermin granted US/EU regulatory designations |
| 27th Apr 2026 7:00 am | RNS | TESARO update on AnaptysBio Inc. litigation |